Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 May;38(5):1023–1026. doi: 10.1128/aac.38.5.1023

Beta-lactams versus glycopeptides in treatment of subcutaneous abscesses infected with Staphylococcus aureus.

C A Wood 1, R M Wisniewski 1
PMCID: PMC188144  PMID: 8067732

Abstract

The antibacterial efficacies of the beta-lactam antibiotics nafcillin and cefazolin were compared with those of the glycopeptide antibiotics vancomycin and teicoplanin in rats with subcutaneous abscesses infected with methicillin-susceptible Staphylococcus aureus. Animals were treated with antibiotics or diluent for 3 or 7 days. Rats receiving any antibiotic treatment, with the exception of teicoplanin-treated animals at day 7, had lower bacterial counts in their abscesses than did controls at days 3 and 7. Rats in the nafcillin and cefazolin treatment groups had lower bacterial counts in their abscesses than did rats in the vancomycin and teicoplanin treatment groups at days 3 and 7. The beta-lactam antibiotics were more effective therapy than the glycopeptide antibiotics in rats with subcutaneous abscesses infected with methicillin-susceptible S. aureus. In vitro, animal, and clinical data comparing beta-lactam and glycopeptide treatment of S. aureus infections were reviewed along with the resulting treatment recommendations.

Full text

PDF
1023

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bailey E. M., Rybak M. J., Kaatz G. W. Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin. Antimicrob Agents Chemother. 1991 Jun;35(6):1089–1092. doi: 10.1128/aac.35.6.1089. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bergan T., Engeset A., Olszewski W. Does serum protein binding inhibit tissue penetration of antibiotics? Rev Infect Dis. 1987 Jul-Aug;9(4):713–718. doi: 10.1093/clinids/9.4.713. [DOI] [PubMed] [Google Scholar]
  3. Bryant R. E., Mazza J. A., Gardner E. M. Effect of abscess milieu on bactericidal activity of LY146032 against staphylococci. Eur J Clin Microbiol. 1987 Apr;6(2):186–188. doi: 10.1007/BF02018206. [DOI] [PubMed] [Google Scholar]
  4. Calain P., Krause K. H., Vaudaux P., Auckenthaler R., Lew D., Waldvogel F., Hirschel B. Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections. J Infect Dis. 1987 Feb;155(2):187–191. doi: 10.1093/infdis/155.2.187. [DOI] [PubMed] [Google Scholar]
  5. Cantoni L., Glauser M. P., Bille J. Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination. Antimicrob Agents Chemother. 1990 Dec;34(12):2348–2353. doi: 10.1128/aac.34.12.2348. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cantoni L., Wenger A., Glauser M. P., Bille J. Comparative efficacy of amoxicillin-clavulanate, cloxacillin, and vancomycin against methicillin-sensitive and methicillin-resistant Staphylococcus aureus endocarditis in rats. J Infect Dis. 1989 May;159(5):989–993. doi: 10.1093/infdis/159.5.989. [DOI] [PubMed] [Google Scholar]
  7. Chambers H. F., Kennedy S. Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis. Antimicrob Agents Chemother. 1990 Apr;34(4):510–514. doi: 10.1128/aac.34.4.510. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Chambers H. F., Miller R. T., Newman M. D. Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy. Ann Intern Med. 1988 Oct 15;109(8):619–624. doi: 10.7326/0003-4819-109-8-619. [DOI] [PubMed] [Google Scholar]
  9. Chambers H. F., Mills J., Drake T. A., Sande M. A. Failure of a once-daily regimen of cefonicid for treatment of endocarditis due to Staphylococcus aureus. Rev Infect Dis. 1984 Nov-Dec;6 (Suppl 4):S870–S874. doi: 10.1093/clinids/6.supplement_4.s870. [DOI] [PubMed] [Google Scholar]
  10. Chambers H. F., Sande M. A. Teicoplanin versus nafcillin and vancomycin in the treatment of experimental endocarditis caused by methicillin-susceptible or -resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1984 Jul;26(1):61–64. doi: 10.1128/aac.26.1.61. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Craven D. E., Kollisch N. R., Hsieh C. R., Connolly M. G., Jr, McCabe W. R. Vancomycin treatment of bacteremia caused by oxacillin-resistant Staphylococcus aureus: comparison with beta-lactam antibiotic treatment of bacteremia caused by oxacillin-sensitive Staphylococcus aureus. J Infect Dis. 1983 Jan;147(1):137–143. doi: 10.1093/infdis/147.1.137. [DOI] [PubMed] [Google Scholar]
  12. Cremieux A. C., Maziere B., Vallois J. M., Ottaviani M., Azancot A., Raffoul H., Bouvet A., Pocidalo J. J., Carbon C. Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography. J Infect Dis. 1989 May;159(5):938–944. doi: 10.1093/infdis/159.5.938. [DOI] [PubMed] [Google Scholar]
  13. Drusano G. L. Role of pharmacokinetics in the outcome of infections. Antimicrob Agents Chemother. 1988 Mar;32(3):289–297. doi: 10.1128/aac.32.3.289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Ena J., Dick R. W., Jones R. N., Wenzel R. P. The epidemiology of intravenous vancomycin usage in a university hospital. A 10-year study. JAMA. 1993 Feb 3;269(5):598–602. [PubMed] [Google Scholar]
  15. Galanakis N., Giamarellou H., Vlachogiannis N., Dendrinos C., Daikos G. K. Poor efficacy of teicoplanin in treatment of deep-seated staphylococcal infections. Eur J Clin Microbiol Infect Dis. 1988 Apr;7(2):130–134. doi: 10.1007/BF01963065. [DOI] [PubMed] [Google Scholar]
  16. Gilbert D. N., Wood C. A., Kimbrough R. C. Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. The Infectious Diseases Consortium of Oregon. Antimicrob Agents Chemother. 1991 Jan;35(1):79–87. doi: 10.1128/aac.35.1.79. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Handwerger S., Tomasz A. Antibiotic tolerance among clinical isolates of bacteria. Rev Infect Dis. 1985 May-Jun;7(3):368–386. doi: 10.1093/clinids/7.3.368. [DOI] [PubMed] [Google Scholar]
  18. Joiner K. A., Onderdonk A. B., Gelfand J. A., Bartlett J. G., Gorbach S. L. A quantitative model for subcutaneous abscess formation in mice. Br J Exp Pathol. 1980 Feb;61(1):97–107. [PMC free article] [PubMed] [Google Scholar]
  19. Karchmer A. W. Staphylococcus aureus and vancomycin: the sequel. Ann Intern Med. 1991 Nov 1;115(9):739–741. doi: 10.7326/0003-4819-115-9-739. [DOI] [PubMed] [Google Scholar]
  20. Kaye D. The clinical significance of tolerance of Staphylococcus aureus. Ann Intern Med. 1980 Dec;93(6):924–926. doi: 10.7326/0003-4819-93-6-924. [DOI] [PubMed] [Google Scholar]
  21. Korzeniowski O., Sande M. A. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: A prospective study. Ann Intern Med. 1982 Oct;97(4):496–503. doi: 10.7326/0003-4819-97-4-496. [DOI] [PubMed] [Google Scholar]
  22. Levine D. P., Cushing R. D., Jui J., Brown W. J. Community-acquired methicillin-resistant Staphylococcus aureus endocarditis in the Detroit Medical Center. Ann Intern Med. 1982 Sep;97(3):330–338. doi: 10.7326/0003-4819-97-3-330. [DOI] [PubMed] [Google Scholar]
  23. Levine D. P., Fromm B. S., Reddy B. R. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med. 1991 Nov 1;115(9):674–680. doi: 10.7326/0003-4819-115-9-674. [DOI] [PubMed] [Google Scholar]
  24. Rajashekaraiah K. R., Rice T., Rao V. S., Marsh D., Ramakrishna B., Kallick C. A. Clinical significance of tolerant strains of Staphylococcus aureus in patients with endocarditis. Ann Intern Med. 1980 Dec;93(6):796–801. doi: 10.7326/0003-4819-93-6-796. [DOI] [PubMed] [Google Scholar]
  25. Small P. M., Chambers H. F. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother. 1990 Jun;34(6):1227–1231. doi: 10.1128/aac.34.6.1227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Sorrell T. C., Packham D. R., Shanker S., Foldes M., Munro R. Vancomycin therapy for methicillin-resistant Staphylococcus aureus. Ann Intern Med. 1982 Sep;97(3):344–350. doi: 10.7326/0003-4819-97-3-344. [DOI] [PubMed] [Google Scholar]
  27. Wood C. A., Finkbeiner H. C., Kohlhepp S. J., Kohnen P. W., Gilbert D. N. Influence of daptomycin on staphylococcal abscesses and experimental tobramycin nephrotoxicity. Antimicrob Agents Chemother. 1989 Aug;33(8):1280–1285. doi: 10.1128/aac.33.8.1280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Wood C. A., Norton D. R., Kohlhepp S. J., Kohnen P. W., Porter G. A., Houghton D. C., Brummett R. E., Bennett W. M., Gilbert D. N. The influence of tobramycin dosage regimens on nephrotoxicity, ototoxicity, and antibacterial efficacy in a rat model of subcutaneous abscess. J Infect Dis. 1988 Jul;158(1):13–22. doi: 10.1093/infdis/158.1.13. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES